Maxalt (Rizatriptan Benzoate)

Rizatriptan is indicated for the acute management of migraine, a neurovascular headache disorder.

• Migraine (acute): Provides rapid relief of headache pain and associated symptoms when taken at the onset of an attack.

• Rizatriptan acts as a selective agonist at serotonin 5‑HT1B and 5‑HT1D receptors located on cranial blood vessels and trigeminal nerve terminals. Activation of these receptors induces vasoconstriction of dilated intracranial arteries and inhibits the release of pro‑inflammatory neuropeptides, thereby reducing migraine pain and associated symptoms.

Rizatriptan may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Dizziness: sensation of light‑headedness.
• Fatigue: feeling unusually tired.
• Dry mouth: reduced salivation.
• Tingling: paresthesia in extremities.
• Chest discomfort: mild pressure or tightness.

Serious or Rare Side Effects

• Coronary vasospasm: chest pain due to reduced coronary blood flow.
• Serotonin syndrome: agitation, hyperthermia, and neuromuscular abnormalities.
• Severe allergic reaction: rash, swelling, or difficulty breathing.
• Hypertension: sudden increase in blood pressure.
• Myocardial infarction: heart attack in susceptible individuals.
• Stroke: cerebrovascular event, particularly in patients with vascular risk factors.

Before prescribing Rizatriptan, evaluate patient-specific risk factors and contraindications.

• Cardiovascular assessment: review history of heart disease, hypertension, or stroke.
• Drug interactions: avoid concurrent use with ergotamine derivatives or MAO inhibitors.
• Dose limitation: do not exceed the prescribed maximum number of tablets per 24‑hour period.
• Hepatic function: use caution in patients with liver impairment.
• Driving caution: advise patients to avoid operating machinery if dizziness occurs.
• Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Rizatriptan can interact with several medication classes, requiring careful management.

Major Interactions (Avoid)

• Ergotamine derivatives: risk of severe vasospasm.
• MAO inhibitors: potential for serotonin syndrome.
• Other triptans: additive vasoconstrictive effects.

Moderate Interactions (Monitor Closely)

• SSRIs/SNRIs: increased risk of serotonin syndrome.
• CYP3A4 inhibitors (e.g., ketoconazole): may raise plasma rizatriptan levels.
• CYP3A4 inducers (e.g., rifampin): may reduce efficacy.
• Antihypertensives: possible attenuation of blood pressure control.
• Antiemetics (e.g., domperidone): may affect gastric motility and absorption.